MRV Newsletter October 2022
MRV’s latest newsletter introduces our new Governance Committee consumer member, highlights the research of Dr Lorey Smith and invites you to the 2022 MRV Scientific Exchange meeting. MRV Newsletter October…
Read More Publications
Relatlimab Plus Nivolumab Approved in Europe for Unresectable or Metastatic Melanoma with PD-L1 <1%
The European Commission has approved the fixed-dose combination of relatlimab plus nivolumab (Opdivo; Opdualag) for use in the frontline treatment of adult and adolescent patients aged 12 years of age and older with advanced or metastatic melanoma and a PD-L1 expression of less than 1% on tumor cells.
Nivolumab/Relatlimab Combo for Treatment of Unresectable or Metastatic Melanoma
The European Commission based its approval of nivolumab/relatlimab for patients with a PD-L1 expression of less than 1% on the results of the phase 2/3 RELATIVITY-047 trial.
FDA Grants Fast Track Designation to KIN-2787 for Select Stage IIB to IV Malignant Melanoma
The FDA has granted a fast track designation to KIN-2787 for use as a potential therapeutic option in patients with BRAF class II or III alteration–positive and/or NRAS mutation–positive, metastatic or unresectable, stage IIB to IV malignant melanoma.